Current approaches and perspectives in the medical treatment of diabetic retinopathy

Pharmacology and Therapeutics

Volumn 103, Issue 2, 2004, Pages 167-177

  Porta, Massimo ^a   Allione, Attilio ^a  

^a UNIVERSITY OF TURIN   (Italy)

Author keywords

Blood glucose control; Blood pressure control; Clinical trial; Diabetic retinopathy; Evidence based medicine; Growth factor

Indexed keywords

ACETYLSALICYLIC ACID; ALDOSE REDUCTASE INHIBITOR; ANTIOXIDANT; BENFOTIAMINE; GROWTH HORMONE; ISOENZYME; PIGMENT EPITHELIUM DERIVED FACTOR; PROTEIN KINASE C; PROTEIN KINASE C INHIBITOR; SOMATOSTATIN; THIAMINE; THIAMINE DERIVATIVE; VASCULOTROPIN;

BLINDNESS; BLOOD GLUCOSE MONITORING; BLOOD PRESSURE REGULATION; DIABETIC RETINOPATHY; DRUG MECHANISM; ENZYME INHIBITION; GLYCOSYLATION; GROWTH HORMONE RELEASE; HUMAN; HYPERTENSION; LASER COAGULATION; PRIORITY JOURNAL; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; RETINA MACULOPATHY; REVIEW; THROMBOCYTE AGGREGATION;

ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANTIHYPERTENSIVE AGENTS; CLINICAL TRIALS; DIABETIC RETINOPATHY; HUMANS; PLATELET AGGREGATION INHIBITORS;

EID: 4444339437     PISSN: 01637258     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pharmthera.2004.07.001     Document Type: Review

References (92)

1. A.P. Adamis, D.T. Shima, M.J. Tolentino, E.S. Gragoudas, N. Ferrara, J. Folkman, P.A. D'Amore, and J.W. Miller Inhibition of vascular endothelial growth factor prevents retinal ischemia-associated iris neovascularization in a nonhuman primate Arch Ophthalmol 114 1996 66 71
2. L.P. Aiello, R.L. Avery, P.G. Arrigg, B.A. Keyt, H.D. Jampel, S.T. Shah, L.R. Pasquale, H. Thieme, M.A. Iwamoto, J.E. Park, H.V. Nguyen, L.P. Aiello, N. Ferrara, and G.L. King Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders N Engl J Med 33 1994 1480 1487
3. L.P. Aiello, M.T. Cahill, and J.S. Wong Systemic considerations in the management of diabetic retinopathy Am J Ophthalmol 132 2001 760 776
4. L.P. Aiello, M.D. Davis, R.C. Milton, J. Sheetz, V. Arora, and L. Vignati Initial results of the protein kinase C beta inhibitor Diabetic Macular Edema Study (PKC-DMES) [abstract] Diabetologia 46 Suppl 2 2003 A42
5. S.J. Aldington, E.M. Kohner, S. Meuer, R. Klein, and A. Sjolie The EURODIAB IDDM Complications Study Group Methodology for retinal photography and assessment of diabetic retinopathy: the EURODIAB IDDM Complications Study Diabetologia 38 1995 437 444
6. C. Arauz-Pacheco, L.C. Ramirez, L. Pruneda, G.E. Sanborn, J. Rosenstock, and P. Raskin The effect of the aldose reductase inhibitor, ponalrestat, on the progression of diabetic retinopathy J Diabetes Complications 6 1992 131 137
7. A. Atherton, D.W. Hill, H. Keen, S. Young, and E.J. Edwards The effect of acute hyperglycaemia on the retinal circulation of the normal cat Diabetologia 18 1980 233 237
8. R. Babaei-Jadidi, N. Karachalias, N. Ahmed, S. Battah, and P. Thornalley Prevention of incipient diabetic nephropathy by high-dose thiamine and benfotiamine Diabetes 52 2003 2110 2120
9. H.G. Blaauwgeers, G.M. Holtkamp, H. Rutten, A.N. Witmer, P. Koolwijk, T.A. Partanen, K. Alitalo, M.E. Kroon, A. Kijlstra, V.W. van Hinsbergh, and R.O. Schlingemann Polarized vascular endothelial growth factor secretion by human retinal pigment epithelium and localization of vascular endothelial growth factor receptors on the inner choriocapillaris: evidence for a trophic paracrine relation Am J Pathol 155 1999 421 428
10. The Blood Pressure Lowering Treatment Trialists' Collaboration Effects of ACE inhibitors, calcium antagonist, and other blood-pressure-lowering drugs: results of prospectively designed overviews of randomized trials Lancet 356 2000 1955 1964
11. A. Bosco, C. Lerario, R.F. Santos, and B.L. Wajchenberg Effect of thalidomide and rosiglitazone on the prevention of diabetic retinopathy in streptozotocin-induced diabetic rats Diabetologia 46 2003 1669 1675
12. E. Chantelau, and E.M. Kohner Why some cases of retinopathy worsen when diabetic control improves Br Med J 315 1997 1105 1106
13. N. Chaturvedi, A.K. Sjolie, J.M. Stephenson, H. Abrahamian, A. Castellarin, Z. Rogulia-Pepeonik, and J.H. Fuller Effect of lisinopril on progression of retinopathy in normotensive people with type 1 diabetes Lancet 35 1998 28 31
14. N. Chaturvedi, A.K. Sjoelie, M. Porta, S.J. Aldington, J.H. Fuller, M. Songini, E.M. Kohner the EURODIAB Prospective Complications Study Group Markers of insulin resistance are strong risk factors for the incidence of retinopathy in type 1 diabetes: findings from the EURODIAB PCS Diabetes Care 24 2001 284 289
15. N. Chaturvedi, A.K. Sjoelie, and A. Svensson The DIabetic Retinopathy Candesartan Trials (DIRECT) Programme, rationale and study design J Renin Angiotensin Aldosterone Syst 3 2002 255 261
16. E.Y. Chew, M.L. Klein, F.L. Ferris III, N.A. Remaley, R.P. Murphy, K. Chantry, B.J. Hoogwerf, and D. Miller Association of elevated serum lipid levels with retinal hard exudate in diabetic retinopathy: Early Treatment Diabetic Retinopathy Study (ETDRS) Report No. 22 Arch Ophthalmol 114 1996 1079 1084
17. T.A. Chowdhury, D. Hopkins, P.M. Dodson, and G.C. Valfidis The role of serum lipids in exudative diabetic maculopathy: is there a place for lipid lowering therapy? Eye 16 2002 689 693
18. J.A. Colwell, P.V. Halushka, K. Sarji, J. Levine, J. Sagel, and R.M. Nair Altered platelet function in diabetes mellitus Diabetes 25 1976 826 831
19. M. Cusik, E.Y. Chew, C.C. Chan, H.S. Kruft, R.P. Muphy, and F.L. Ferris III Histopathology and regression of retinal hard exudates in diabetic retinopathy after reduction of elevated serum lipid levels Ophthalmology 110 2003 2126 2133
20. The DAMAD Study Group Effect of aspirin alone and aspirin plus dipyridamole in early diabetic retinopathy. A multicentre randomized controlled clinical trial Diabetes 38 1989 491 498
21. M.D. Davis, M.R. Fisher, R.E. Gangnon, F. Barton, L.M. Aiello, E.Y. Chew, F.L. Ferris III, and G.L. Knatterud Risk factors for high-risk proliferative diabetic retinopathy and severe visual loss: Early Treatment Diabetic Retinopathy Study Report No. 18 Invest Ophthalmol Vis Sci 39 1998 233 252
22. J.P. De La Cruz, J.A. Gonzalez-Correa, A. Guerrero, and F.S. de la Cuesta Pharmacological approach to diabetic retinopathy Diabetes Metab Res Rev 20 2004 91 113
23. The Diabetes Control and Complications Trial (DCCT) Research Group The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus N Engl J Med 329 1993 977 986
24. The Diabetes Control and Complications Trial (DCCT) Research Group The effect of intensive diabetes treatment on the progression of diabetic retinopathy in insulin-dependent diabetes mellitus Arch Ophthalmol 113 1995 36 51
25. The Diabetes Control and Complications Trial (DCCT) Research Group Lifetime benefits and costs of intensive therapy as practiced in the Diabetes Control and Complications Trial JAMA 276 1996 1409 1415
26. Diabetic Retinopathy Study Research Group Photocoagulation treatment of proliferative diabetic retinopathy: the second report of DRS findings Ophthalmology 85 1978 82 106
27. U. Di Mario, and G. Pugliese 15th Golgi lecture: from hyperglycaemia to the dysregulation of vascular remodelling in diabetes Diabetologia 44 2001 674 692
28. W. Drexler, U. Morgner, R.K. Ghanta, F.X. Karter, J.S. Shuman, and J.G. Fujimoto Ultra-high-resolution ophthalmic optical coherence tomography Nat Med 7 2001 502 507
29. Early Treatment Diabetic Retinopathy Study Research Group Fundus photographic risk factors for progression of diabetic retinopathy. ETDRS Report No. 12 Ophthalmology 98 1991 823 833
30. Early Treatment of Diabetic Retinopathy Study Group Effects of aspirin treatment of diabetic retinopathy. ETDRS Report No. 8 Ophthalmology 98 1991 757 765
31. Early Treatment Diabetic Retinopathy Study Research Group Grading diabetic retinopathy from stereoscopic colour fundus photographs-an extension of the modified Airlie House classification ETDRS Report No. 10 Ophthalmology 98 1991 786 806
32. R.O. Estacio, B.W. Jeffers, N. Gifford, and R.W. Schrier Effect of blood pressure control on diabetic microvascular complications in patients with hypertension and type 2 diabetes Diabetes Care 23 2000 B54 B64
33. F.L. Ferris III, M.D. Davis, and L.M. Aiello Treatment of diabetic retinopathy N Engl J Med 341 1999 667 678
34. G. Gao, Y. Li, D. Zhang, S. Gee, and C. Crosson Unbalanced expression of VEGF and PEDF in ischemia-induced retinal neovascularization FEBS Lett. 489 2001 270 276
35. R.E. Gilbert, D.J. Kelly, A.J. Cox, J.L. Wilkinson-Berka, J.R. Rumble, T. Osicka, S. Panagiotopoulos, V. Lee, E.C. Hendrich, G. Jerums, and M.E. Cooper Angiotensin converting enzyme inhibition reduces retinal overexpression of vascular endothelial growth factor and hyperpermeability in experimental diabetes Diabetologia 43 2000 1360 1367
36. D. Giugliano, A. Ceriello, and G. Paolisso Oxidative stress and diabetic vascular complications Diabetes Care 19 1996 257 267
37. M.B. Grant, R. Cooper-DeHoff, R.N. Mames, S. Caballero, C. Fitzgerald, K.S. Estes, and K.M. Hazariwala The efficacy of octreotide in the therapy of severe non proliferative and early proliferative diabetic retinopathy. A randomized controlled study Diabetes Care 23 2000 504 509
38. J.E. Grunwald, C.E. Riva, and B.L. Petrig Strict control of glycaemia: effects on blood flow in the large retinal vessels and in the macular microcirculation Br J Ophthalmol 79 1995 735 741
39. H.P. Hammes, X. Du, D. Edelstein, T. Taguchi, T. Matsumura, Q. Ju, J. Lin, A. Bierhaus, P. Nawroth, D. Hannak, M. Neumaier, R. Bergfeld, I. Giardino, and M. Brownlee Benfotiamine blocks three major pathways of hyperglycemic damage and prevents experimental diabetic retinopathy Nat Med 9 2003 294 299
40. R. Harper, C.N. Ennis, A.P. Heaney, B. Sheridan, M. Gormley, A.B. Atkinson, G.D. Johnston, and P.M. Bell A comparison of the effects of low and conventional dose thiazide diuretic on insulin action in hypertensive patients with NIDDM Diabetologia 38 1995 853 859
41. The Heart Outcomes Prevention Evaluation (HOPE) study investigators N Engl J Med 342 2000 145 153
42. I.M. Hogeboom van Buggenum, B.C. Polak, J.W. Reichert-Thoen, W.A. de Vries-Knoppert, V.W. van Hinsbergh, and G.J. Tangelder Angiotensin converting enzyme inhibiting therapy is associated with lower vitreous vascular endothelial growth factor concentrations in patients with proliferative diabetic retinopathy Diabetologia 45 2002 203 209
43. H. Ishii, M.R. Jirousek, C. Takagi, P. Xia, A. Clermont, S.E. Bursell, T.S. Kern, L.M. Ballas, Wf. Haeth, L.E. Stramm, E.P. Feener, and G.L. King Amelioration of vascular dysfunctions in diabetic rats by an oral PKC beta inhibitor Science 272 1996 728 731
44. A.M. Joussen, V. Poulaki, N. Mitsiades, B. Kirchhof, K. Koizumi, S. Dohmen, and A.P. Adamis Nonsteroidal anti-inflammatory drugs prevent early diabetic retinopathy via TNF-suppression FASEB J 16 2002 438 440
45. Z.A. Khan, and S. Chakrabarti Growth factors in proliferative diabetic retinopathy Exp Diabesity Res 4 2003 287 301
46. R. Klein, B.E.K. Klein, and S.E. Moss Prevalence of diabetes mellitus in southern Wisconsin Am J Epidemiol 119 1984 54 61
47. B.E.K. Klein, R. Klein, and S.E. Moss Prevalence of cataracts in a population-based study of persons with diabetes mellitus Ophthalmology 92 1985 1191 1196
48. B.E.K. Klein, S.E. Moss, R. Klein, and T.S. Surawicz The Wisconsin Epidemiologic Study of Diabetic Retinopathy. XIII. Relationship of serum cholesterol to retinopathy and hard exudate Ophthalmology 98 1991 1261 1265
49. B.E.K. Klein, R. Klein, and S.E. Moss Incidence of cataract surgery in the Wisconsin Epidemiologic Study of Diabetic Retinopathy Am J Ophthalmol 119 1995 295 300
50. R. Klein, B.E. Klein, K.E. Lee, K.J. Cruickshanks, and S.E. Moss The incidence of hypertension in insulin-dependent diabetes Arch Intern Med 156 1996 622 627
51. D. Koya, and G.L. King Protein kinase C activation and the development of diabetic complications Diabetes 47 1998 859 866
52. M. Kunisaki, S.-E. Bursell, A.C. Clermont, H. Ishii, L.M. Ballas, M.R. Jirousek, F. Umeda, H. Nawata, and G.L. King Vitamin E prevents diabetes-induced abnormal retinal blood flow via the diacylglycerol-protein kinase C pathway Am J Physiol 269 1995 E239 E246
53. M. La Selva, E. Beltramo, F. Pagnozzi, E. Bena, P.A. Molinatti, G.M. Molinatti, and M. Porta Thiamine corrects delayed replication and decreases production of lactate and advanced glycation end-products in bovine retinal and human umbilical vein endothelial cells cultured under high glucose conditions Diabetologia 39 1996 1263 1268
54. M. Lonchampt, L. Pennel, and J. Duhault Hyperoxia/normoxia-driven retinal angiogenesis in mice: a role for angiotensin II Invest Ophthalmol Vis Sci 42 2001 429 432
55. B. Mallet, B. Vialettes, S. Haroche, P. Escoffier, P. Gastaut, J.-P. Taubert, and P. Vague Stabilization of severe proliferative diabetic retinopathy by long-term treatment with SMS 201-995 Diabete Metab 18 1992 438 444
56. E.J. Mayer-Davis, R.A. Bell, B.A. Reboussin, J. Rushing, J.A. Marshall, and R.F. Hamman Antioxidant nutrient intake and diabetic retinopathy: the San Louis Valley diabetes study Ophthalmology 105 1998 2264 2270
57. R.C. Milton, L.P. Aiello, M.D. Davis, M.J. Sheetz, V. Arora, and L. Vignati Initial results of the protein kinase C beta inhibitor Diabetic Retinopathy Study (PKC-DRS) [abstract] Diabetologia 46 Suppl 2 2003 A42
58. M. Mizutani, C. Gerhardinger, and M. Lorenzi Muller cell changes in human diabetic retinopathy Diabetes 47 1998 815 820
59. F. Mori, T. Hikichi, T. Nagaoka, J. Takahashi, N. Kitaya, and A. Yoshida Inhibitory effect of losartan, an AT1 angiotensin II receptor antagonist, on increased leucocyte entrapment in retinal microcirculation of diabetic rats Br J Ophthalmol 86 2002 1172 1174
60. Y. Nagisa, A. Shintani, and S. Nakagawa The angiotensin II receptor antagonist candesartan cilexetil (TCV-116) ameliorates retinal disorders in rats Diabetologia 44 2001 883 888
61. P. Nagpala, A.B. Malik, P.T. Voung, and H. Lum Protein kinase Cb1 overexpression augments phorbol ester-induced increase endothelial permeability J Cell Physiol 166 1996 249 255
62. T. Nishikawa, D. Edelstein, and M. Brawnlee The missing link: a single unifying mechanism for diabetic complications Kidney Int Suppl 58 2000 S26 S30
63. T. Nishikawa, D. Edelstein, X.L. Du, S. Yamagishi, T. Matsumura, Y. Kaneda, M.A. Yorek, D. Neebe, P.J. Oates, H.P. Hamnes, I. Giardino, and M. Brownlee Normalizing mitochondrial superoxide production blocks three pathways of hyperglycaemic damage Nature 404 2000 87 790
64. J. Pirart Diab̀te et complications dégéné ratives. Présentation d'une étude prospective portant sur 4400 cas observés entre 1947 et 1973 Diabete Metab 1 1977 97 256
65. T. Pollare, H. Lithell, I. Selimus, and C. Berne Sensitivity to insulin during treatment with atenolol and metoprolol: a randomized, double blind study of effects on carbohydrate and lipoprotein metabolism in hypertensive patients Br Med J 298 1989 1152 1157
66. M. Porta, and F. Bandello Diabetic retinopathy: a clinical update Diabetologia 45 2002 1617 1634
67. M. Porta, A.K. Sjolie, N. Chaturvedi, L. Stevens, R. Roltiers, M. Veglio, J.H. Fuller the EURODIAB Prospective Complications Study Group Risk factors for progression to proliferative diabetic retinopathy in the EURODIAB prospective complications study Diabetologia 44 2001 2203 2209
68. V. Poulaki, W. Qin, A.M. Joussen, P. Hurlbut, S.J. Wiegand, J. Rudge, G.D. Yancopoulos, and A.P. Adamis Acute intensive insulin therapy exacerbates diabetic blood retinal barrier breakdown via hypoxia-inducible factor 1-alpha and VEGF J Clin Invest 109 2002 805 815
69. J.E. Poulsen Recovery from retinopathy in a case of diabetes with Simmonds' disease Diabetes 2 1953 7 12
70. E.D.U. Powell, and R.A. Field Diabetic retinopathy and rheumatoid arthritis Lancet 2 1964 17 18
71. Q. Qiao, S. Keinamen-Kiukaanniemi, and E. Laara The relationship between hemoglobin levels and diabetic retinopathy J Clin Epidemiol 50 1997 153 158
72. S.M. Rassam, V. Patel, and E.M. Kohner The effect of experimental hypertension on retinal vascular autoregulation in humans: a mechanism for the progression of diabetic retinopathy Exp Physiol 80 1995 53 68
73. W.G. Robinson Jr., N.M. Laver, J.L. Jacot, J.P. Glover, M.D. Basso, P. Blouin, and T.C. Hohman Diabetic-like retinopathy ameliorated with the aldose reductase inhibitor WAY-121,509 Invest Ophthalmol Vis Sci 37 1996 1149 1156
74. N. Saito, M. Kimura, A. Kuchiba, and Y. Itokawa The relationship between blood thiamine levels and dietary thiamine content in diabetic outpatients and healthy subjects J Nutr Sci Vitaminol 33 1987 431 438
75. G.S. Schultz, and M.B. Grant Neovascular growth factors Eye 5 1991 170 180
76. A.M. Sharma, J. Janke, K. Gorzelniak, S. Engeli, and F. Luft Angiotensin blockade prevents type 2 diabetes by formation of fat cells Hypertension 40 2002 609 611
77. R. Simó, A. Lecube, L. Sararols, J. García-Arumi-, R.M. Segura, R. Casamitjana, and C. Hernández Deficit of somatostatin-like immunoreactivity in the vitreous fluid of diabetic patients possible role in the development of proliferative diabetic retinopathy Diabetes Care 25 2002 2282 2286
78. R. Singh, A. Barden, T. Mori, and L. Beilin Advanced glycation end-products: a review Diabetologia 44 2001 129 146
79. L.E. Smith, W. Shen, C. Perruzzi, S. Soker, F. Kinose, X. Xu, G. Robinson, S. Driver, J. Bischoff, B. Zhang, J.M. Schaeffer, and D.R. Senger Regulation of vascular endothelial growth factor-dependent retinal neovascularization by insulin-like growth factor-1 receptor Nat Med 5 1999 1390 1395
80. Sorbinil Retinopathy Trial Research Group A randomized trail of sorbinil, an aldose reductase inhibitor, in diabetic retinopathy Doc Ophthalmol 78 1991 153 159
81. V. Stellmach, S.E. Crawford, W. Zhou, and N. Bouck Prevention of ischemia-induced retinopathy by the natural ocular antiangiogenic agent pigment epithelium-derived factor Proc Natl Acad Sci USA 98 2001 2593 2597
82. I. Suzuma, Y. Hata, A. Clermont, F. Pokras, S.L. Rook, K. Suzuma, E.P. Feener, and L.P. Aiello Cyclic stretch and hypertension induced retinal VEGF-R2 (KDR) expression: potential mechanisms for exacerbation of diabetic retinopathy by hypertension Diabetes 50 2001 444 454
83. The TIMAD Study Group Ticlopidine treatment reduces the progression of nonproliferative diabetic retinopathy Arch Ophthalmol 108 1990 1577 1583
84. C. Trautner, B. Haastert, G. Giani, and M. Berger Incidence of blindness in southern Germany between 1990 and 1998 Diabetologia 44 2001 147 150
85. UKPDS Group Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33) Lancet 352 1998 837 853
86. UKPDS Group Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38 BMJ 317 1998 703 713
87. J.M. Van Gerven, J.P. Boot, H.H. Lemkes, and J.A. Van Best Effects of aldose reductase inhibition with tolrestat on diabetic retinopathy in a six months double blind trial Doc Ophthalmol 87 1994 335 365
88. H.A. van Leiden, J.M. Dekker, A.C. Moll, G. Nijpels, R.J. Heine, L.M. Bouter, C.D. Stehouwer, and B.C. Polak Blood pressure, lipids, and obesity are associated with retinopathy: the Hoorn study Diabetes Care 25 2002 1320 1325
89. M. Wakisaka, M. Yoshinari, S. Nakamura, T. Asano, K. Sonoki, A. Shi, Y. Takata, and M. Fujishima Suppression of sodium-dependent glucose uptake by captopril improves high-glucose induced morphological and functional changes of cultured bovine retinal pericytes Microvasc Res 58 1999 215 223
90. A.N. Witmer, H.G. Blaauwgeers, H.A. Weich, K. Alitalo, G.F. Vrensen, and R.O. Schlingemann Altered expression patterns of VEGF receptors in human diabetic retina and in experimental VEGF-induced retinopathy in monkey Invest Ophthalmol Vis Sci 43 2002 849 857
91. Writing Team for the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Research Group Effect of intensive therapy on the microvascular complications of type 1 diabetes mellitus JAMA 287 2002 2563 2569
92. J.Z. Zhang, L. Gao, M. Widness, X. Xi, and T.S. Kem Captopril inhibits glucose accumulation in retinal cells in diabetes Invest Ophthalmol Vis Sci 44 2003 40001 40005